Posttranscriptional cell cycle-dependent regulation of human FANCC expression

Blood

Volumn 95, Issue 12, 2000, Pages 3970-3977

  Heinrich, Michael C ^a,b   Silvey, Kirsten V ^a   Stone, Stacie ^a   Zigler, Amy J ^a   Griffith, Diana J ^a   Montalto, Michelle ^a   Chai, Lin ^a   Zhi, Yu ^a   Hoatlin, Maureen E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP C COMPLEMENTATION PROTEIN; GENE PRODUCT; MESSENGER RNA; PROTEASOME; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL CYCLE; CELL NUCLEUS; CELL SYNCHRONIZATION; CONTROLLED STUDY; CYTOPLASM; FANCONI ANEMIA; GENE EXPRESSION REGULATION; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA ANALYSIS; TRANSLATION REGULATION;

EID: 0034659782     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3970.012k33_3970_3977     Document Type: Article

References (54)

1. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. ematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84:1650-1655.
2. dos Santos CC, Gavish H, Buchwald M. Fanconi anemia revisited: old ideas and new advances. Stem Cells. 1994;12:142-153.
3. Joenje H, Mathew C, Gluckman E. Fanconi anemia research: current status and prospects. Eur J Cancer. 1995;31A:268-272.
4. Fanconi G. Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.), I: Clinical aspects. Semin Hematol. 1967;4:233-240.
5. Fanconi G. Familiäre intantile periziosaartige anämie (perniziöses blutbild und konstitution). Jb Kinderheilk. 1927;117:257-280.
6. Socie G, Gluckman E, Raynal B, et al. Bone marrow transplantation for Fanconi anemia using low-dose cyclophosphamide/thoracoabdominal irradiation as conditioning regimen: chimerism study by the polymerase chain reaction. Blood. 1993;82:2249-2256.
7. Liu JM, Buchwald M, Walsh CE, Young NS. Fanconi anemia and novel strategies for therapy. Blood. 1994;84:3995-4007.
8. Ishida R, Buchwald M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res. 1982;42:4000-4006.
9. Weksberg R, Buchwald M, Sargent P, Thompson MW, Siminovitch L. Specific cellular defects in patients with Fanconi anemia. J Cell Physiol. 1979;101:311-323.
10. Joenje H, Oostra AB, Wijker M, et al. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet. 1997;61:940-944.
11. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation [published erratum appears in Nature 1992 Jul 30; 358:434]. Nature. 1992;356:763-767.
12. Lo ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nature Genet. 1996;14:320-323.
13. de Winter JP, Waisfisz Q, Rooimans MA, et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nature Genet. 1998;20: 281-283.
14. Whitney M, Thayer M, Reifsteck C, et al. Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. Nature Genet. 1995;11:341-343.
15. Waisfisz Q, Saar K, Morgan NV, et al. The Fanconi anemia group E gene, FANCE, maps to chromosome 6p. Am J Hum Genet. 1999;64: 1400-1405.
16. Youssoufian H. Localization of Fanconi anemia C protein to the cytoplasm of mammalian cells. Proc Natl Acad Sci U S A. 1994;91:7975-7979.
17. Yamashita T, Barber DL, Zhu Y, Wu N, D'Andrea AD. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc Natl Acad Sci U S A. 1994;91:6712-6716.
18. Garcia-Higuera I, D'Andrea AD. Regulated binding of the Fanconi anemia proteins, FANCA and FANCC [letter]. Blood. 1999;93:1430-1432.
19. Hoshino T, Wang J, Devetten MP, et al. Molecular chaperone GRP94 binds to the Fanconi anemia group C protein and regulates its intracellular expression. Blood. 1998;91:4379-4386.
20. Joenje H, Youssoufian H, Kruyt FA, et al. Expression of the Fanconi anemia gene FAC in human cell lines: lack of effect of oxygen tension. Blood Cells Mol Dis. 1995;21:182-191.
21. Youssoufian H, Auerbach AD, Verlander PC, Steimle V, Mach B. Identification of cytosolic proteins that bind to the Fanconi anemia complementation group C polypeptide in vitro: evidence for a multimeric complex. J Biol Chem. 1995;270: 9876-9882.
22. Kruyt FA, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Youssoufian H. Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. Blood. 1998;92:3050-3056.
23. Hoatlin M, Zhi Y, Ball H, et al. A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi Anemia group C protein and PLZF. Blood. 1999;94:3737-3747.
24. Garcia-Higuera I, Kuang Y, Naf D, Wasik J, D'Andrea AD. Fanconi Anemia proteins FANCA. FANCC, and FANCG/XRCC9 interact in a functional nuclear comples. Mol.Cell.Biol. 1999;19: 4866-4873.
25. Hoatlin ME, Christianson TA, Keeble WW, et al. The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells. Blood. 1998;91:1418-1425.
26. Heinrich MC, Hoatlin ME, Zigler AJ, et al. DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood. 1998;91:275-287.
27. Yarbro JW. Further studies on the mechanism of action of hydroxyurea. Cancer Res. 1968;28: 1082-1087.
28. Notterman D, Young S, Wainger B, Levine AJ. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity. Oncogene. 1998;17:2743-2751.
29. Kallioniemi OP, Visakorpi T, Holli K, Isola JJ, Rabinovitch PS. Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. Cytometry. 1994;16:250-255.
30. Lo TFJ, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997; 5:137-148.
31. Kupfer GM, Yamashita T, Naf D, Suliman A, Asano S, D'Andrea AD. The Fanconi Anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. Blood. 1997;90:1047-1054.
32. Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 1968;28:1559-1565.
33. Boshart M, Weber F, Jahn G, Dorsch-Häsler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. 1985;41: 521-530.
34. Savoia A, Garcia-Higuera I, D'Andrea AD. Nuclear localization of the Fanconi anemia protein FANCC is required for functional activity. Blood. 1999;93:4025-4026.
35. Brandeis M, Hunt T. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 1996; 15:5280-5289.
36. Lahav-Baratz S, Sudakin V, Ruderman JV, Hershko A. Reversible phosphorylation controls the activity of cyclosome-associated cyclin-ubiquitin ligase. Proc Natl Acad Sci U S A. 1995;92:9303-9307.
37. Buchwald M, Moustacchi E. Is Fanconi anemia caused by a defect in the processing of DNA damage? Mutat Res. 1998;408:75-90.
38. Naf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD. Functional activity of the fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol Cell Biol. 1998;18:5952-5960.
39. Youssoufian H. Cytoplasmic localization of FAC is essential for the correction of a prerepair defect in Fanconi anemia group C cells. J Clin Invest. 1996;97:2003-2010.
40. Kupfer GM, Naf D, Suliman A, Pulsipher M, D'Andrea AD. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nature Genet. 1997;17:487-490.
41. Yamashita T, Kupfer GM, Naf D, et al. The Fanconi anemia pathway requires FAA phosphorylation and FAA/FAC nuclear accumulation Proc Natl Acad Sci U S A. 1998;95:13085-13090.
42. Waisfisz Q, de Winter JP, Kruyt FAE, et al. Evidence for a physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci U S A. 1999;96:10320-10325.
43. Spencer CM, Eberwine J. Cytoplasmic proteins interact with a translational control element in the protein-coding region of proopiomelanocortin mRNA. DNA Cell Biol. 1999;18:39-49.
44. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274:1652-1659.
45. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol. 1997; 9:788-799.
46. Murakami Y, Matsufuji S, Kameji T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature. 1992; 360:597-599.
47. Bercovich Z, Kahana C. Involvement of the 20S proteasome in the degradation of ornithine decarboxylase. Eur J Biochem. 1993;213:205-210.
48. Peters JM. Subunits and substrates of the anaphase-promoting complex. Exp Cell Res. 1999; 248:339-349.
49. Kruyt FA, Dijkmans LM, Arwert F, Joenje H. Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase. Cancer Res. 1997;57:2244-2251.
50. Hershko A, Ganoth D, Sudakin V, et al. Components of a system that ligales cyclin to ubiquitin and their regulation by the protein kinase cdc2. J Biol Chem. 1994;269:4940-4946.
51. Craiu A, Gaczynska M, Akopian T, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 1997;272:13437-13445.
52. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995;268:726-731.
53. Mellgren RL. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mucalpain and the 20 S proteasome. J Biol Chem. 1997;272:29899-29903.
54. de Winter JP, Rooimans MA, van Der Weel L, et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet. 2000;24:15-16.